



SUPPLEMENTARY DATA

**Supplementary Figure 1.** Pearson Correlation between plasma FFA ratio (Acipimox/Basal) and TGD/SSPI ratio (Acipimox/Basal) in obese NGT and T2DM groups. Black dots: Obese NGT; white dots: T2DM;  $p \leq 0.05$ .



SUPPLEMENTARY DATA

**Supplementary Figure 2.** Hepatic insulin resistance and Adipose Tissue Insulin Sensitivity at baseline and after Acipimox treatment. **A.** Hepatic insulin resistance index in Obese NGT and T2DM groups; **B.** Adipose tissue insulin resistance index in Obese NGT and T2DM groups.



SUPPLEMENTARY DATA

**Supplementary Figure 3.** Mitochondrial ROS production at baseline and after Acipimox treatment. **A.** Obese NGT group. **B.** T2DM groups. G/M: glutamate/malate; G/M+RO: glutamate/malate plus Rotenone Pyr: Pyruvate; Pyr+RO: Pyruvate plus Rotenone; SucR: Succinate plus Rotenone; SucR+AA: Succinate plus Rotenone and Antimycin A; PCM: Palmitoyl-Carnitine 0.5 mM; PCM+R: Palmitoyl-Carnitine 0.5 mM plus Rotenone; PC+AA: Palmitoyl-Carnitine 0.5 mM plus Antimycin A; PC+R+AA: Palmitoyl-Carnitine 0.5 mM plus Rotenone plus Antimycin A \* $p < 0.05$ .

